ArticleInternational journal of surgery (London, England)2026
Genetic architecture of primary sclerosing cholangitis: shared pathways with inflammatory bowel disease and gut-liver axis mediation.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deciphering potential significances of biliary microbiome in cholelithiasis and cholangiocarcinoma.Antonie van Leeuwenhoek · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary sclerosing cholangitis (PSC) is a chronic liver disease strongly linked to inflammatory bowel disease (IBD), yet its causal genetic drivers and the mechanisms underlying this comorbidity remain poorly understood. This study aimed to identify causal genes for PSC and elucidate the role of the gut-liver axis in its pathogenesis.
methodsWe performed a multi-omics study integrating transcriptome-wide association studies (TWAS), summary Mendelian randomization (SMR), and colocalization using PSC GWAS data (2871 cases; 12 019 controls) and tissue-specific eQTL data. Bidirectional Mendelian randomization (MR) was employed to dissect causal relationships between identified genes, PSC, IBD, gut microbiota, and metabolites.
resultsSeven genes were prioritized as potential causal targets for PSC: MMEL1, FUT2, PRKD2, C4A, HLA-DMA, VARS2, and RPL23AP1, with evidence supported by colocalization and expression in relevant immune and intestinal tissues. Bidirectional MR confirmed a causal link from IBD to PSC and identified shared genetic pathways. Crucially, MR analysis provided causal evidence for the role of specific gut microbiota in PSC risk, including increased risk with higher abundance of Clostridium and Veillonella . Mediation analyses further implicated FUT2 and HLA-DMA in modulating PSC risk via the gut microbiota, particularly through taxa such as Clostridium, Butyrivibrio crossotus , and Rhodospirillaceae .
conclusionThis study delineates PSC's genetic architecture by identifying novel causal genes and confirms the gut-liver axis's central role in its pathogenesis. We propose an integrated "dual-hit" model where host genetic susceptibility constitutes the "first hit" and subsequent gut dysbiosis acts as a "second hit." These findings offer novel therapeutic targets and a mechanistic framework with potential implications for patient management in liver transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.